Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 6, 2003, Pages 497-504

  Yukawa, E ^a   Nonaka, T ^b   Yukawa, M ^c   Higuchi, S ^d   Kuroda, T ^b   Goto, Y ^c  

^a DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Clearance; Clonazepam; Drug drug interaction; NONMEM; Valproic acid

Indexed keywords

CLONAZEPAM; VALPROIC ACID;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; EPILEPSY; FEMALE; HEALTH CARE; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MODEL; NONLINEAR SYSTEM; PHARMACOEPIDEMIOLOGY; SEX DIFFERENCE;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CLONAZEPAM; DRUG INTERACTIONS; FEMALE; HUMANS; INFANT; JAPAN; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACOEPIDEMIOLOGY; VALPROIC ACID;

EID: 0346962899     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00528.x     Document Type: Article

References (30)

1. Baille TA, Sheffels PR (1995) Valproic acid: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th edn. New York: Raven Press, 589-604.
2. Levy RH, Shen DD (1995) Valproic acid: absorption, distribution and excretion. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs, 4th edn. New York: Raven Press, 605-619.
3. Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Annals of Pharmacotherapy, 32, 554-563.
4. Eschenhol VE (1973) Untersuchungen uber das Schicksal des antikonvulsivums clonazepam in organismus der ratte, des hundes und des menschen. Arzneimittelforsch, 23, 390-400.
5. Klotz U, Kangas L, Kanto J (1980) Clinical pharmacokinetics of benzodiazepines. Progress in Pharmacology, 3, 1-71.
6. Greenblatt DJ, Miller LG, Shader RI (1987) Clonazepam pharmacokinetics, brain uptake, and receptor interactions. Journal of Clinical Psychiatry, 48(Suppl.), 4-11.
7. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA (1993) Identification of the human and animal hepatic cytochromes P-450 involved in clonazepam metabolism. Fundamental and Clinical Pharmacology, 7, 69-75.
8. Beal SL, Sheiner LB (eds) (1992) NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California at San Francisco.
9. Sheiner LB, Benet LZ (1985) Premarketing observational studies of population pharmacokinetics of new drugs. Clinical Pharmacology and therapeutics, 38, 481-487.
10. Yukawa E (1995) Population-based investigation of carbamazepine relative clearance using routine clinical pharmacokinetic data in Japan: a multiple peak approach feasibility study for pharmacokinetic screening. Clinical Drug Investigation, 10, 29-39.
11. Yukawa E (1995) A feasibility study of multiple peak approach for pharmacokinetic screening: population-based investigation of valproic acid relative clearance using routine clinical pharmacokinetic data. Journal of Pharmacy and Pharmacology, 47, 1048-1052.
12. Nonaka T, Inoue K, Kuroda T, Ogata H, Mitsudome A (1995) Serum clonazepam levels in epileptic children. Medical Bulletin Fukuoka University, 17, 173-181.
13. Yukawa E, Satou M, Nonaka T, Yukawa M, Ohdo S, Higuchi S, Kuroda T, Goto Y (2002) Pharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. Journal of Clinical Pharmacology, 42, 81-88.
14. Yukawa E, To H, Ohdo S, Higuchi S, Aoyama T (1997) Population-based investigation of valproic acid relative clearance using non-linear mixed effects modeling: Influence of drug-drug interaction and patient characteristics. Journal of Clinical Pharmacology, 37, 1160-1167.
15. Huang CY, McLead JG, Sampson D, Hensley WJ (1974) Clonazepam in the treatment of epilepsy. Medical Journal of Australia, 2, 5-8.
16. Inami M, Hara T (1977) The effects of clonazepam on the plasma diphenylhydantoin level in epileptic patients. Electroencephalogr. Clinical Neurophysiology, 43, 497.
17. Benetello P, Furlanut M, Testa G, Santi R (1977) Effect of benzodiazepines on serum levels of phenobarbital and diphenylhydantoin. Riv Farmacol Ter, 8, 109-112.
18. Saavedra IN, Aquilera LI, Faure E, Galdames DG (1985) Phenytoin/clonazepam interaction. Therapeutic Drug Monitoring, 7, 481-484.
19. Lehtovaara R, Bardy A, Hari R, Majuri H (1978) Sodium valproate and clonazepam interactions with phenytoin and carbamazepine. In: Meinardi H, Rowan AJ, eds. Advances in epileptology, 1977: psychology, pharmacotherapy, and new diagnostic approaches. Amsterdam: Swets and Zeitlinger, 269-270.
20. Lai AA, Levy RH, Cutler RE (1978) Time-course of interaction between carbamazepine and clonazepam in normal man. Clinical Pharmacology and Therapeutics, 24, 316-323.
21. Nanda RN, Johnson RH, Keogh HJ, Lambie DG, Melville ID (1977) Treatment of epilepsy with clonazepam and its effect on other anticonvulsants. Journal of Neurology, Neurosurgery and Psychiatry, 40, 538-543.
22. Sadeque AJM, Korzekwa KR, Gonzalez FJ, Rettie AE (1995) Identification of human liver cytochrome P-450 isoenzymes responsible for the formation of 4 ene-valproic Acid (abstract). International Society for the Study of Xenobiotics Proceeding, 8, 87.
23. Sadeque AJM, Korzekwa KR, Gonzalez F, Rettie AE (1994) Metabolism of valproic acid by human liver microsomes (abstract). International Society for the Study of Xenobiotics Proceeding, 6, 273.
24. Hurst SI, Labroo R, Carlson SP, Mather GG, Levy RH (1997) In vitro inhibition profile of valproic acid for cytochrome P-450 (abstract). International Society for Study of Xenobiotics Proceeding, 12, 64.
25. Scheyer RD, Mattson RH (1995) Valproate: interactions with other drugs. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edn. New York: Raven Press, 621-631.
26. Thomson AH, Brodie MJ (1992) Pharmacokinetic optimisation of anticonvulsant therapy. Clinical Pharmacokinetics, 23, 216-230.
27. Hvidberg EF, Dam M. (1976) Clinical pharmacokinetics of anticonvulsants. Clinical Pharmacokinetics, 1, 161-188.
28. Dhillon S, Richens A (1982) Valproate acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology, 13, 553-560.
29. Wager ML, Graves NM, Leppik IE, Remmel RP, Shumaker RC, Ward DL, Perhach JL (1994) The effect of felbamate on valproic acid disposition. Clinical Pharmacology and Therapeutics, 56, 494-502.
30. Hopper WD, Franklin ME, Glue P et al. (1996) Effect of felbamate on valproic acid disposition in healthy volunters: Inhibition of β-oxidation. Epilepsia, 37, 91-97.